The Food and Drug Administration (FDA) has given the go-ahead for a controversial clinical trial to test whether marijuana can be used to treat combat veterans with post-traumatic stress disorder (PTSD).
The long-delayed study is sponsored by the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) and had been delayed since 2021 due to several objections by the agency related to the health effects of inhaling high-potency cannabis. The FDA had also objected to the study’s “self-titration” dosing method which allows the participants to smoke as much cannabis as they feel is necessary to relieve their PTSD symptoms.
MAPS announced the approval of the clinical trial on Nov. 20 and said that the FDA no longer objects to the inhalation of smoke and participants being allowed to choose their preferred.
H/T: www.themirror.com
